Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai

Zhang, Zhen Xin; Román, Gustavo C.; Hong, Zhen; Wu, Cheng Bing; Qu, Qiu Ming; Huang, Jue Bing; Zhou, Bing; Geng, Zhi Ping; Wu, Ji Xing; Wen, Hong Bo; Zhao, Heng; Zahner, Gwendolyn E. P.

doi:10.1016/s0140-6736(05)17909-4

Cited by 183 publications

(137 citation statements)

References 5 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…The PD prevalence is estimated around 1.7% in people over 65 years of age in China (Zhang et al., 2005). Parkinson's disease (PD) is characterized by the cardinal motor symptoms, such as bradykinesias, rigidity, postural instability, resting tremor, and nonmotor symptoms including psychiatric problems, autonomic disturbances, pain, fatigue and impaired cognition in executive functioning, memory and spatial behavior during the early stage of the disease (Chaudhuri & Odin, 2010; Vingerhoets, Verleden, Santens, Miatton, & De Reuck, 2003).…”

Section: Introductionmentioning

confidence: 99%

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Chen

Yang²,

et al. 2018

Brain and Behavior

View full text Add to dashboard Cite

ObjectiveTo detect the aberrant expression of circulating miRNAs and explore the potential early diagnostic biomarkers in patients with Parkinson's disease (PD).MethodsPlasma samples were collected from 25 treatment‐naïve PD‐diagnosed patients and 25 healthy controls followed by a real‐time PCR‐based miRNA screening analysis of neuron disease‐related miRNAs.ResultsA subset of miRNAs with aberrant expression levels in the plasma of PD‐diagnosed patients were identified including upregulation of miR‐27a and downregulation of let‐7a, let‐7f, miR‐142‐3p, and miR‐222 with the AUC values more than 0.8 derived from the receiver operating characteristic curves.ConclusionsThe high sensitivity and specificity of the circulating miRNAs may enable early diagnosis of PD. The study provides a group of novel miRNA candidates for detecting PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Chen

Yang²,

et al. 2018

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…First described by James Parkinson in 1817 [1], Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD), with an incidence of 1.7% in individuals aged over 65 years [2]. PD is characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) of the midbrain.…”

Section: Introductionmentioning

confidence: 99%

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic Target

Chen¹,

Chen²,

Pu³

2018

Eur Neurol

View full text Add to dashboard Cite

Background: Parkinson’s disease (PD) is characterized by the selective loss of dopaminergic neurons in the midbrain. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. There is increasing evidence that leucine-rich repeat kinase 2 (LRRK2) plays a significant role in PD pathophysiology. Summary: Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, we discuss the role of LRRK2 in PD and recent progress in the use of LRRK2 inhibitors as therapeutic agents. Key Messages: LRRK2 plays a significant role in the pathophysiology of PD, and pharmacological inhibition of LRRK2 has become one of the most promising potential therapies for PD. Further research is warranted to determine the functions of LRRK2 and expand the applications of LRRK2 inhibitors in PD treatment.

show abstract

“…It is estimated globally that prevalence of PD is 0.3% in the general population and 1%–2% in persons 60–65 years and older [2], [3]. In China, PD prevalence is estimated as 1.70% in people aged more than 65 years old [4]. In order to seek for alleviation, patients with PD often turn to complementary and alternative medicine [5].…”

Section: Introductionmentioning

confidence: 99%

Tai Chi for Improvement of Motor Function, Balance and Gait in Parkinson's Disease: A Systematic Review and Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

BackgroundRecently, several studies assessed the effectiveness of Tai Chi for Parkinson's disease (PD), but the role of Tai Chi in the management of PD remained controversial. Therefore, the purpose of this systematic review is to evaluate the evidence on the efficacy of Tai Chi for PD.MethodsSix English and Chinese electronic databases, up to April 2014, were searched to identify relevant studies. The risk of bias in eligible studies was assessed by Cochrane Collaboration's tools. The primary outcomes were motor function, balance and gait in individuals with PD. Standardized mean difference (SMD) and 95% confidence intervals (CI) of random-effect model were calculated. And heterogeneity was assessed based on the I2statistic.Results7 randomized controlled trials and 1 non-randomized controlled trial were eligible. The aggregated results suggested that Tai Chi showed beneficial effects in improving motor function (SMD, −0.57; 95% CI −1.11 to −0.04; p = 0.03), balance (SMD, 1.22; 95% CI 0.80 to 1.65; p<0.00001) and functional mobility (SMD, 1.06; 95% CI 0.68 to 1.44; p<0.00001) in patients with PD, but not in improving gait velocity (SMD, −0.02; 95% CI −0.58 to 0.54; p = 0.94), step length (SMD, −0.00; 95% CI −0.57 to 0.56; p = 0.99), or gait endurance (SMD, 0.53; 95% CI −0.07 to 1.12; p = 0.08). Comparing with other active therapies, however, Tai Chi only showed better effects in improving balance (SMD, 0.74; 95% CI 0.38 to 1.10; p<0.0001).ConclusionTai Chi should be a valid complementary and alternative therapy for PD, especially in improving motor function and balance. However, more studies with long follow-up are warrant to confirm the current finding of Tai Chi for PD.

show abstract

Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai

Cited by 183 publications

References 5 publications

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic Target

Tai Chi for Improvement of Motor Function, Balance and Gait in Parkinson's Disease: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About